Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 10:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,617 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus, Adult Onset Clear all
Completed Phase 3 Interventional Results available

An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus

NCT00135330
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
exenatide, rosiglitazone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
19
States / cities
Phoenix, Arizona • San Francisco, California • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 5, 2026, 10:35 AM EDT
Completed Phase 2 Interventional

Evaluation of an Orally Administered Medication When Taken in Conjunction With Pramlintide

NCT00044707
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Pramlintide acetate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Oct 5, 2026, 10:35 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes

NCT00099853
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Vildagliptin, pioglitazone, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 5, 2026, 10:35 AM EDT
Completed Phase 3 Interventional

Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes

NCT00044395
View directory record Official record
Conditions
Diabetic Neuropathies, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Ruboxistaurin mesylate
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
19
States / cities
Mesa, Arizona • Irvine, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2007 · Synced Oct 5, 2026, 10:35 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Vitamin D and Omega-3 Supplementation for Preventing Diabetes

NCT01633177
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Vitamin D3, Omega-3 fatty acid (fish oil), Vitamin D3 placebo, Fish oil placebo
Dietary Supplement · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
22,220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 5, 2026, 10:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Incentivized Smoking Cessation for Diabetics

NCT03527667
View directory record Official record
Conditions
Smoking Cessation, Diabetes Mellitus, Type 2
Interventions
Financial incentives
Behavioral
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 6, 2019 · Synced Oct 5, 2026, 10:35 AM EDT
Completed Phase 3 Interventional

A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.

NCT00717457
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
exenatide, taspoglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
87
States / cities
Haleyville, Alabama • Mobile, Alabama • Montgomery, Alabama + 78 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 5, 2026, 10:35 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Metformin Use and Vitamin B12 Deficiency

NCT01136512
View directory record Official record
Conditions
Vitamin B12 Deficiency, Type 2 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
20 Years to 80 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2013 · Synced Oct 5, 2026, 10:35 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens

NCT01365507
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
25
States / cities
Concord, California • Los Angeles, California • Montclair, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Oct 5, 2026, 10:35 AM EDT
Completed Phase 2 Interventional

AMG 151 Amgen Protocol Number 20100761

NCT01464437
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
AMG 151, Placebo, Metformin
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Oct 5, 2026, 10:35 AM EDT
Completed Phase 3 Interventional

Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment

NCT01336751
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, 75% insulin lispro protamine suspension and 25 % insulin lispro injection
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 79 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 18, 2011 · Synced Oct 5, 2026, 10:35 AM EDT
Completed Not applicable Interventional

Evaluating Outcomes for Ethnically Diverse Patients With Type 2 Diabetes Participating in a Diabetes Education Program

NCT03464812
View directory record Official record
Conditions
Type2 Diabetes
Interventions
DSMES
Behavioral
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 5, 2026, 10:35 AM EDT
Completed Phase 1 Interventional

A Drug-Drug Interaction Study of GK Activator (2) and Glyburide in Patients With Type 2 Diabetes.

NCT00388986
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
GK Activator (2), Glyburide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Cypress, California • Honolulu, Hawaii • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 5, 2026, 10:35 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186

NCT05694741
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
AZD0186, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 5, 2026, 10:35 AM EDT
Completed No phase listed Observational

Postpartum Glucose Tolerance With Levonorgesterel IUD Use in Women With Recent Gestational Diabetes

NCT01022645
View directory record Official record
Conditions
Gestational Diabetes, Glucose Intolerance, Type 2 Diabetes, Intrauterine Contraception
Interventions
Mirena (Levonorgestrel IUD), Paragard (Copper IUD ) or Tubal Ligation
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Oct 5, 2026, 10:35 AM EDT
Terminated Phase 2 Interventional

Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin

NCT00814372
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
MBX-102, Placebo, Actos, Metformin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Burbank, California • Los Angeles, California • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 5, 2026, 10:35 AM EDT
Completed Phase 4 Interventional

NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes

NCT00095446
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Oct 5, 2026, 10:35 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise

NCT01809327
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canagliflozin 100 mg, Canagliflozin 300 mg, Metformin XR
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Encinitas, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 5, 2026, 10:35 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Multiple Dose Study Of PF-05161704 In Healthy Volunteers

NCT01202266
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PF-05161704 or Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 11, 2011 · Synced Oct 5, 2026, 10:35 AM EDT
Enrolling by invitation Not applicable Interventional

Population Health Management for KPNC Members With Newly Diagnosed Diabetes: A Randomized Trial of a Proactive and Augmented Initial Care Strategy

NCT06906653
View directory record Official record
Conditions
Type 2 Diabetes, Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes (T2D)
Interventions
Augmented Initial Type 2 Diabetes Care
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 74 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pleasanton, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 5, 2026, 10:35 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

NCT02787551
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide, exenatide extended-release, albiglutide, dulaglutide, Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
74
States / cities
Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 5, 2026, 10:35 AM EDT
Completed Phase 1 Interventional

Experimental Study to Validate the Modified Glucose Disposal Test

NCT01152372
View directory record Official record
Conditions
Diabetes
Interventions
Insulin, glucose and staple isotopes
Procedure
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2011 · Synced Oct 5, 2026, 10:35 AM EDT
Not listed No phase listed Observational

Prediabetes and Type 2 Diabetes Data Collection Study

NCT04503239
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Pre-diabetes
Interventions
G6
Device
Lead sponsor
DexCom, Inc.
Industry
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Lemon Grove, California • Las Vegas, Nevada • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 5, 2026, 10:35 AM EDT
Completed Not applicable Interventional

Reducing Type 2 Diabetes Diagnostic Delays Using Decision Support

NCT02199769
View directory record Official record
Conditions
Diabetes, Prediabetes
Interventions
Clinical Decision Support
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
747 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Oct 5, 2026, 10:35 AM EDT